MA47022A - Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique - Google Patents
Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxiqueInfo
- Publication number
- MA47022A MA47022A MA047022A MA47022A MA47022A MA 47022 A MA47022 A MA 47022A MA 047022 A MA047022 A MA 047022A MA 47022 A MA47022 A MA 47022A MA 47022 A MA47022 A MA 47022A
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- effective process
- cell bonding
- conjugates
- bonding agent
- Prior art date
Links
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662292018P | 2016-02-05 | 2016-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47022A true MA47022A (fr) | 2018-12-12 |
Family
ID=58159509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047022A MA47022A (fr) | 2016-02-05 | 2017-02-03 | Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210299265A1 (fr) |
EP (1) | EP3411077A1 (fr) |
JP (1) | JP2019510741A (fr) |
KR (1) | KR20180105233A (fr) |
CN (1) | CN108601848A (fr) |
AU (1) | AU2017213858A1 (fr) |
CA (1) | CA3013125A1 (fr) |
MA (1) | MA47022A (fr) |
RU (1) | RU2018130108A (fr) |
SG (1) | SG11201806478PA (fr) |
TW (1) | TW201731532A (fr) |
WO (1) | WO2017136623A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201703599VA (en) * | 2014-11-19 | 2017-06-29 | Immunogen Inc | Process for preparing cell-binding agent-cytotoxic agent conjugates |
AU2017345454A1 (en) | 2016-10-19 | 2019-05-30 | Invenra Inc. | Antibody constructs |
MX2019007019A (es) | 2016-12-22 | 2019-08-16 | Univ Degli Studi Magna Graecia Catanzaro | Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer. |
CN113227127A (zh) | 2018-06-05 | 2021-08-06 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
SG11202012257VA (en) * | 2018-06-26 | 2021-01-28 | Immunogen Inc | Immunoconjugates targeting adam9 and methods of use thereof |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (fr) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotique C-15003 PHO et sa préparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (fr) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | Composes 4,5-deoxymaytansinoide et leur procede de preparation |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (fr) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Animaux non humains transgeniques capables de produire des anticorps heterologues |
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
CA2076465C (fr) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
IL111748A0 (en) | 1993-12-03 | 1995-01-24 | Zeneca Ltd | Proteins |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5958872A (en) | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
WO1999006587A2 (fr) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Nouvelle methode et nouveau phage d'identification d'une sequence d'acide nucleique |
TW593241B (en) | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
CA2398136A1 (fr) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
DZ3494A1 (fr) | 2001-01-05 | 2002-07-11 | Pfizer | Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline |
EA010570B1 (ru) | 2002-11-07 | 2008-10-30 | Иммьюноджен, Инк. | Антитело к cd33 и способы его применения |
AU2004259398A1 (en) | 2003-06-27 | 2005-02-03 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
KR101200133B1 (ko) | 2004-06-01 | 2012-11-13 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
US20060045877A1 (en) | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
EP1817341A2 (fr) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Anticorps et immunoconjugues mis au point |
EP1819359B1 (fr) | 2004-12-09 | 2015-03-18 | Janssen Biotech, Inc. | Immunoconjugues anti-integrines, methodes pour leur production et leur application |
AU2006220709B2 (en) | 2005-03-04 | 2012-09-06 | Biogen Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
EP1914242A1 (fr) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
RU2011138951A (ru) | 2009-02-23 | 2013-03-27 | Сайтомкс Терапьютикс, Инк. | Пропротеины и способы их применения |
AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
KR20220017432A (ko) | 2010-02-24 | 2022-02-11 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
LT2544719T (lt) | 2010-03-12 | 2019-10-25 | Debiopharm Int Sa | Cd37 surišančios molekulės, ir jų imunokonjugatai |
WO2012019024A2 (fr) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Molécules se liant à her3 et leurs immunoconjugués |
AU2011323316B2 (en) | 2010-11-03 | 2016-02-25 | Immunogen, Inc. | Cytotoxic agents comprising new ansamitocin derivatives |
WO2012095347A1 (fr) | 2011-01-10 | 2012-07-19 | Technische Universität München | Ligand phosphinate à base de trialsacyclononane et son utilisation en imagerie moléculaire |
MY183977A (en) * | 2011-02-15 | 2021-03-17 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
US8795673B2 (en) * | 2011-03-29 | 2014-08-05 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
SG195172A1 (en) * | 2011-06-21 | 2013-12-30 | Immunogen Inc | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
-
2017
- 2017-02-03 SG SG11201806478PA patent/SG11201806478PA/en unknown
- 2017-02-03 KR KR1020187025528A patent/KR20180105233A/ko unknown
- 2017-02-03 JP JP2018540718A patent/JP2019510741A/ja active Pending
- 2017-02-03 WO PCT/US2017/016344 patent/WO2017136623A1/fr active Application Filing
- 2017-02-03 TW TW106103674A patent/TW201731532A/zh unknown
- 2017-02-03 EP EP17707135.4A patent/EP3411077A1/fr not_active Withdrawn
- 2017-02-03 CN CN201780009779.5A patent/CN108601848A/zh active Pending
- 2017-02-03 US US16/075,263 patent/US20210299265A1/en not_active Abandoned
- 2017-02-03 RU RU2018130108A patent/RU2018130108A/ru not_active Application Discontinuation
- 2017-02-03 AU AU2017213858A patent/AU2017213858A1/en not_active Abandoned
- 2017-02-03 CA CA3013125A patent/CA3013125A1/fr not_active Abandoned
- 2017-02-03 MA MA047022A patent/MA47022A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201806478PA (en) | 2018-08-30 |
US20210299265A1 (en) | 2021-09-30 |
TW201731532A (zh) | 2017-09-16 |
EP3411077A1 (fr) | 2018-12-12 |
KR20180105233A (ko) | 2018-09-27 |
CN108601848A (zh) | 2018-09-28 |
CA3013125A1 (fr) | 2017-08-10 |
RU2018130108A3 (fr) | 2020-06-05 |
WO2017136623A8 (fr) | 2017-10-12 |
JP2019510741A (ja) | 2019-04-18 |
AU2017213858A1 (en) | 2018-08-16 |
WO2017136623A1 (fr) | 2017-08-10 |
RU2018130108A (ru) | 2020-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54253A (fr) | Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines | |
IL246954B (en) | A medical preparation containing a senolytic factor for the treatment of osteoarthritic joints | |
MA47022A (fr) | Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique | |
MA52906A (fr) | Procédé de préparation d'amg 416 | |
IL247722A0 (en) | Pharmaceutical preparations containing active medicinal compounds for the treatment of hematological cancers | |
DK3068392T3 (da) | Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme | |
FR2991320B1 (fr) | Procede de preparation d'amines methylees | |
MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
BR112016021012A2 (pt) | composições farmacêuticas de compostos terapeuticamente ativos. | |
HK1252562A1 (zh) | 苯並咪唑衍生物用於夜間酸突破的用途 | |
HK1250717A1 (zh) | 製備乙酰半乳糖胺酸衍生物的方法 | |
MA49472A (fr) | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole | |
MA42423A (fr) | Procédé de préparation d'un revêtement | |
FR3038312B1 (fr) | Procede de preparation de polyols | |
FR3023287B1 (fr) | Procede de preparation de methylmercaptan | |
HUP1600232A2 (en) | Process for preparation of optically active beraprost | |
MA42964A (fr) | Préparation pharmaceutique anti-vieillissement | |
MA50517A (fr) | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole | |
MA51165A (fr) | Procédés de préparation de composés de (cyclopentyl[d]pyrimidin-4-yl)pipérazine | |
MA42264A (fr) | Procédé de préparation d'oltipraz | |
MA51339A (fr) | Procédé de préparation de composés pyrimidinyl-4-aminopyrazole | |
MA49555A (fr) | Procédé amélioré de préparation d'imetelstat | |
FR3024729B1 (fr) | Procede de preparation du trioxane | |
MA50371A (fr) | Procédé de préparation de dérivés spiro | |
FR3011839B1 (fr) | Procede de preparation de derives d'acetamidophenyle |